|
DK3246042T3
(da)
|
2009-11-02 |
2019-10-14 |
Univ Emory |
Lægemiddelresistent immunterapi til behandling af cancer
|
|
EP2948544A4
(en)
|
2013-01-28 |
2016-08-03 |
St Jude Childrens Res Hospital |
CHIMERIC RECEPTOR WITH NKG2D SPECIFICITY FOR CELL THERAPY AGAINST CANCER AND INFECTION DISEASES
|
|
EP3783098A1
(en)
|
2013-05-14 |
2021-02-24 |
Board Of Regents, The University Of Texas System |
Human application of engineered chimeric antigen receptor (car) t-cells
|
|
CA2913052A1
(en)
|
2013-05-24 |
2014-11-27 |
Board Of Regents, The University Of Texas System |
Chimeric antigen receptor-targeting monoclonal antibodies
|
|
WO2015080981A1
(en)
*
|
2013-11-27 |
2015-06-04 |
Baylor College Of Medicine |
Csgp4-specific chimeric antigen receptor for cancer
|
|
KR102375998B1
(ko)
|
2014-02-14 |
2022-03-21 |
더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 |
키메라 항원 수용체 및 제조방법
|
|
DK3143134T3
(da)
|
2014-05-15 |
2021-01-04 |
Nat Univ Singapore |
Modificerede, naturlige dræberceller og anvendelser deraf
|
|
BR112017001183A2
(pt)
|
2014-07-21 |
2017-11-28 |
Novartis Ag |
tratamento de câncer usando receptor de antígeno quimérico anti-bcma humanizado
|
|
TWI719942B
(zh)
|
2014-07-21 |
2021-03-01 |
瑞士商諾華公司 |
使用ｃｄ３３嵌合抗原受體治療癌症
|
|
CA2964783C
(en)
|
2014-11-05 |
2024-01-23 |
Board Of Regents, The University Of Texas System |
Chimeric antigen receptors (car) to selectively target protein complexes
|
|
JP2017537622A
(ja)
*
|
2014-12-02 |
2017-12-21 |
ロジャー・ウィリアムズ・ホスピタル |
がんを治療するための方法及び組成物
|
|
JP6797803B2
(ja)
*
|
2014-12-31 |
2020-12-09 |
セルジーン コーポレイション |
ナチュラルキラー細胞を用いて血液障害、固形腫瘍、又は感染性疾患を治療する方法
|
|
ES2818103T3
(es)
|
2015-01-16 |
2021-04-09 |
Juno Therapeutics Inc |
Anticuerpos y receptores de antígenos quiméricos específicos para ROR1
|
|
US11304976B2
(en)
|
2015-02-18 |
2022-04-19 |
Enlivex Therapeutics Ltd |
Combination immune therapy and cytokine control therapy for cancer treatment
|
|
US11596652B2
(en)
|
2015-02-18 |
2023-03-07 |
Enlivex Therapeutics R&D Ltd |
Early apoptotic cells for use in treating sepsis
|
|
US11497767B2
(en)
|
2015-02-18 |
2022-11-15 |
Enlivex Therapeutics R&D Ltd |
Combination immune therapy and cytokine control therapy for cancer treatment
|
|
US11000548B2
(en)
|
2015-02-18 |
2021-05-11 |
Enlivex Therapeutics Ltd |
Combination immune therapy and cytokine control therapy for cancer treatment
|
|
US11318163B2
(en)
|
2015-02-18 |
2022-05-03 |
Enlivex Therapeutics Ltd |
Combination immune therapy and cytokine control therapy for cancer treatment
|
|
EP3865139B1
(en)
|
2015-02-18 |
2023-05-03 |
Enlivex Therapeutics Rdo Ltd |
Combination immune therapy and cytokine control therapy for cancer treatment
|
|
WO2016170541A1
(en)
|
2015-04-21 |
2016-10-27 |
Enlivex Therapeutics Ltd. |
Therapeutic pooled blood apoptotic cell preparations and uses thereof
|
|
ES2965437T3
(es)
*
|
2015-09-03 |
2024-04-15 |
Uab Res Found |
Células T modificadas genéticamente resistentes a fármacos y procedimientos de utilización de las mismas
|
|
EP4006056A1
(en)
|
2016-02-02 |
2022-06-01 |
Fred Hutchinson Cancer Research Center |
Anti-ror1 antibodies and uses thereof
|
|
CN109069539A
(zh)
|
2016-02-18 |
2018-12-21 |
恩立夫克治疗有限责任公司 |
用于癌症治疗的联合免疫疗法和细胞因子控制疗法
|
|
ES2983739T3
(es)
*
|
2016-08-18 |
2024-10-24 |
Uab Res Found |
Composiciones y procedimientos para la inmunoterapia del cáncer
|
|
US11421005B2
(en)
*
|
2016-12-09 |
2022-08-23 |
The Uab Research Foundation |
Chimeric chlorotoxin receptors
|
|
CN110376718A
(zh)
*
|
2016-12-30 |
2019-10-25 |
玉晶光电(厦门)有限公司 |
光学成像镜头
|
|
BR112019019917A2
(pt)
|
2017-03-27 |
2020-04-22 |
Nat Univ Singapore |
receptores quiméricos nkg2d truncados e seus usos em imunoterapia de células exterminadoras naturais
|
|
CA3056591A1
(en)
|
2017-03-27 |
2018-10-04 |
National University Of Singapore |
Stimulatory cell lines for ex vivo expansion and activation of natural killer cells
|
|
US10561686B2
(en)
*
|
2018-01-12 |
2020-02-18 |
Innovative Cellular Therapeutics CO., LTD. |
Modified cell expansion and uses thereof
|
|
EP3749685A4
(en)
|
2018-02-09 |
2021-12-22 |
National University of Singapore |
ACTIVATOR CHEMERIC RECEPTORS AND THEIR USES IN NATURAL KILLING CELL IMMUNOTHERAPY
|
|
JP7334985B2
(ja)
|
2018-04-02 |
2023-08-29 |
ナショナル ユニヴァーシティー オブ シンガポール |
免疫細胞で発現される膜結合抗サイトカイン非シグナル伝達バインダーによるヒトサイトカインの中和
|
|
US10869888B2
(en)
|
2018-04-17 |
2020-12-22 |
Innovative Cellular Therapeutics CO., LTD. |
Modified cell expansion and uses thereof
|
|
TWI890660B
(zh)
|
2018-06-13 |
2025-07-21 |
瑞士商諾華公司 |
Bcma 嵌合抗原受體及其用途
|
|
EP3844186A4
(en)
|
2018-08-29 |
2022-08-17 |
National University of Singapore |
METHOD OF SPECIFIC STIMULATION OF SURVIVAL AND EXPANSION OF GENETICALLY MODIFIED IMMUNE CELLS
|
|
US12240915B2
(en)
|
2018-08-30 |
2025-03-04 |
Innovative Cellular Therapeutics Holdings, Ltd. |
Chimeric antigen receptor cells for treating solid tumor
|
|
US10918667B2
(en)
|
2018-11-20 |
2021-02-16 |
Innovative Cellular Therapeutics CO., LTD. |
Modified cell expressing therapeutic agent and uses thereof
|
|
CA3120563A1
(en)
|
2018-11-26 |
2020-06-04 |
Nkarta, Inc. |
Methods for the simultaneous expansion of multiple immune cell types, related compositions and uses of same in cancer immunotherapy
|
|
EP3773918A4
(en)
|
2019-03-05 |
2022-01-05 |
Nkarta, Inc. |
CD19 DIRECTED CHIMERIC ANTIGEN RECEPTORS AND THEIR USES IN IMMUNOTHERAPY
|
|
US12076343B2
(en)
|
2020-02-19 |
2024-09-03 |
Innovative Cellular Therapeutics Holdings, Ltd. |
Engineered safety in cell therapy
|
|
EP3915576A1
(en)
*
|
2020-05-28 |
2021-12-01 |
Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron |
Chimeric antigen receptors specific for p95her2 and uses thereof
|
|
US12043654B2
(en)
|
2020-06-02 |
2024-07-23 |
Innovative Cellular Therapeutics Holdings, Ltd. |
Anti-GCC antibody and CAR thereof for treating digestive system cancer
|
|
JP2024537991A
(ja)
|
2021-10-14 |
2024-10-18 |
アーセナル バイオサイエンシズ インコーポレイテッド |
共発現されるｓｈＲＮＡと論理ゲートシステムとを有する免疫細胞
|
|
JP2026504619A
(ja)
*
|
2022-11-07 |
2026-02-06 |
ネオイミューンテック， インコーポレイテッド |
非メチル化ｍｇｍｔプロモーターを含む腫瘍を治療する方法
|
|
IL322949A
(en)
|
2023-03-03 |
2025-10-01 |
Arsenal Biosciences Inc |
Systems targeting PSMA and CA9
|